Calcitonin gene-related peptide monoclonal antibodies and medication-overuse headache: stopping excessive pain medication is still necessary

Medication-overuse headache affects 1 to 2% of the global population and is often associated with chronic migraine. This condition significantly impacts the lives of patients, as well as their families, and it poses a major economic burden due to lost productivity and medical costs. The present narr...

Full description

Saved in:
Bibliographic Details
Published inArquivos de neuro-psiquiatria Vol. 83; no. 9; pp. 1 - 4
Main Author Rocha-Filho, Pedro Augusto Sampaio
Format Journal Article
LanguageEnglish
Published Germany Thieme Revinter Publicações 01.09.2025
Subjects
Analgesics
Analgesics - adverse effects
Antibodies, Monoclonal - therapeutic use
Calcitonin Gene-Related Peptide - antagonists & inhibitors
Calcitonin Gene-Related Peptide - immunology
Headache
Headache Disorders, Secondary
Headache Disorders, Secondary - chemically induced
Headache Disorders, Secondary - drug therapy
Headache Disorders, Secondary - prevention & control
Humans
Migraine Disorders
Migraine Disorders - drug therapy
Review
Tension-Type Headache
Therapeutics
Online AccessGet full text

Cover

More Information
Summary:Medication-overuse headache affects 1 to 2% of the global population and is often associated with chronic migraine. This condition significantly impacts the lives of patients, as well as their families, and it poses a major economic burden due to lost productivity and medical costs. The present narrative review is part of a controversy session. We argue that reversing the behavior of overusing symptomatic pain medications is important for the treatment of this type of headache. To support this argument, the article reviews and critically analyzes the relevant literature on the subject.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0004-282X
1678-4227
1678-4227
DOI:10.1055/s-0045-1809332